3 November 2026 Sydney, Australia

Quotation of New Options

Nyrada Inc. (ASX:NYR), a clinical-stage biotechnology company focused on developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions, is pleased to advise that the Company has applied for the quotation on the ASX of the Company's new class of options (Options).

Each option has an exercise price of AU$0.93 and an exercise period ending on 25 September 2028 and gives the holder the right to receive one (1) CHESS Depositary Interest (CDI) and one (1) Piggyback Option upon exercise and payment of the exercise price.

Each Piggyback Option gives the holder the right to receive one (1) CDI upon exercise and payment of the exercise price. Notwithstanding, when an Option is exercised, no Piggyback Options will be granted until the exercise period for the Options has expired.

Pursuant to the Option Prospectus (released on 12 October 2026), the Company issued an aggregate of 9,197,050 free attaching Options on the following basis:

1. 8,316,537 Options to institutional, professional and sophisticated investors who participated in the Company's $12 million Share Placement announced on 21 September 2026, with the Stage 1 placement of CDIs to non-related parties completed on 25 September 2026; and

2. 880,513 Options to Security Purchase Plan participants, with the placement of CDIs to non-related parties completed on 30 October 2026.

Please refer to the two Appendix 2As dated 30 October 2026 for further details on the quotation of the Options.

Schedule 1 attached to this release lists the Top 20 Option Holders in compliance with Listing Rule 3.10.5(a) and a Distribution Schedule under Listing Rule 3.10.5 (b).

The ASX ticker for the Options will be announced to the ASX, once the quotation process is completed.

-ENDS-

Nyrada Inc. Level 22/23, Salesforce Tower, 180 George Street, Sydney NSW 2000 ARBN 625 401 818

About Xolatryp®

Xolatryp is a small-molecule inhibitor of TRPC3/6/7 channels designed to limit excessive Ca^{2+} entry related to multiple disease pathologies.

A Phase I clinical trial to assess the safety, tolerability, and pharmacokinetics has been successfully completed and a Phase IIa clinical trial has commenced to assess the safety and preliminary efficacy of Xolatryp in reducing cardiac reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing percutaneous coronary intervention (PCI).

Key Links:

Cardioprotection

- PROTECT-MI website - https://www.protect-mi.com
- PROTECT-MI NIH Entry - https://bit.ly/4cB2fF9
- FDA IND Feedback - https://bit.ly/4zyu9dZ
- Phase IIa factsheet - https://bit.ly/4bcDlKj
- Preclinical cardioprotection study 1a - https://bit.ly/4sigwMZ
- Preclinical cardioprotection study 1b - https://bit.ly/4rmOsXn
- Preclinical cardioprotection study 2 - https://bit.ly/40jHpUg

Oncology

- Preclinical cardiomyopathy study - https://bit.ly/4yR9BgD
- Preclinical cardiomyopathy pilot study - https://bit.ly/4xJH3Fj
- Preclinical anti-tumour study - https://bit.ly/49rWOa0

Neuroprotection

- Preclinical traumatic brain injury study - https://bit.ly/40fhrRT
- Preclinical stroke study - https://bit.ly/4sygHmH

Foundations

- US Patent Grant - https://bit.ly/4yUqMyf
- Phase I results - https://bit.ly/3Nt0GzH
- Preclinical mitochondria stabilisation study - https://bit.ly/4yiZUHa
- GLP study results - https://bit.ly/4d8VYkX
- CSANZ Conference Poster - https://bit.ly/4A9ROmf

Corporate

- Latest presentation slides - https://bit.ly/46FM9Xq

About Nyrada Inc.

Nyrada Inc. is a clinical stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp®, has shown efficacy in preclinical cardioprotection, neuroprotection, and oncology models and has completed a first-in-human Phase I clinical trial. A Phase IIa clinical trial has commenced to assess the safety and preliminary efficacy of Xolatryp in reducing cardiac reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing PCI. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

www.nyrada.com

Authorised by Mr. James Bonnar, Managing Director and CEO on behalf of the Board.

Investor & Media Enquiries:
Dimitri Burshtein
T: 0491 789 391
E: info@nyrada.com

Company Secretary:
David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.

AUTOMIC
ABN: 27 152 260 814

1300 288 664 (within australia)
+61 2 9698 5414 (international)
hello@automic.com.au
www.automic.com.au

Level 5, 126 Phillip Street,
Sydney NSW 2000

GPO Box 5193,
Sydney NSW 2000

Top Holders Grouped Report

Nyrada Inc

Security Class(es): **ASX TICKER TBA** - OPT EXP 25/09/2028 @ $0.93

Display Top: 20

As at Date: 30-Oct-2026

Position	Holder Name	Holding	% IC
1	CITICORP NOMINEES PTY LIMITED	1,258,885	13.69%
2	NETWEALTH INVESTMENTS LIMITED <WRAP SERVICES A/C>	1,188,998	12.93%
3	JUBEC PTY LTD <JUBEC AF A/C>	604,839	6.58%
4	SHAW AND PARTNERS LTD	337,500	3.67%
5	ABN AMRO CLEARING AUSTRALIA NOMINEES PTY LTD <CUSTODIAN A/C>	274,118	2.98%
6	KYRIACO BARBER PTY LTD	269,987	2.94%
7	MORGAN STANLEY AUSTRALIA SECURITIES (NOMINEE) PTY LIMITED <NO 1 ACCOUNT>	257,057	2.80%
8	BLJ TECHNOLOGIES PTY LTD	156,003	1.70%
8	DRM TECHNOLOGIES PTY LTD	156,003	1.70%
9	HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED - A/C 2	154,235	1.68%
10	BAUMGARTNER PRIVATE CAPITAL GMBH	143,949	1.57%
11	MR PAUL HART	137,070	1.49%
12	SEAFORTH BLUE PTY LTD <THE PAUL MADDEN S/F A/C>	120,969	1.32%

AUTOMIC
ABN: 27 152 260 814

1300 288 664 (within australia)
+61 2 9698 5414 (international)
hello@automic.com.au
www.automic.com.au

Level 5, 126 Phillip Street,
Sydney NSW 2000

GPO Box 5193,
Sydney NSW 2000

Position	Holder Name	Holding	% IC
13	CERTANE CT PTY LTD <BC1>	120,968	1.32%
14	VARASALV PTY LTD <BERNARD ROHAN SF A/C>	112,500	1.22%
14	ARIJAM PTY LTD <ALSTER FAMILY A/C>	112,500	1.22%
15	HELUSS NOMINEES PTY LTD <SUSS SUPER FUND A/C>	111,885	1.22%
16	JOJO ENTERPRISES PTY LTD <SFI FAMILY A/C>	111,456	1.21%
17	CAYMAN EMERGING MANAGER PLATFORM (2) SPC MWP PENDULUM PARTNERSHIP SP	102,823	1.12%
17	BILGOLA NOMINEES PTY LIMITED	102,823	1.12%
17	ORCA CAPITAL AG	102,823	1.12%
18	FOXTAIL PTY LTD	101,835	1.11%
19	EXOSPHERE INVESTMENTS PTY LTD	90,230	0.98%
20	MR MICHAEL BENEDICT COOKSON	90,000	0.98%
	TOTALS	**6,219,456**	**67.62%**
	Total Issued Capital	**9,197,050**	**100.00%**

Report generated on 30-Oct-2026 at 09:18 AM

AUTOMIC
ABN: 27 152 260 814

1300 288 664 (within australia)
+61 2 9698 5414 (international)
hello@automic.com.au
www.automic.com.au

Level 5, 126 Phillip Street,
Sydney NSW 2000

GPO Box 5193,
Sydney NSW 2000

Holdings Range Report

Nyrada Inc

Security Class(es): **ASX TICKER TBA** - OPT EXP 25/09/2028 @ $0.93

As at Date: 30-Oct-2026

Holding Ranges	Holders	Total Units	% Issued Share Capital
above 0 up to and including 1,000	1	605	0.01%
above 1,000 up to and including 5,000	8	24,369	0.26%
above 5,000 up to and including 10,000	13	90,254	0.98%
above 10,000 up to and including 100,000	87	3,042,596	33.08%
above 100,000	22	6,039,226	65.66%
TOTALS	**131**	**9,197,050**	**100.00%**

Report generated on 30-Oct-2026 at 09:18 AM